we welcome and and call. market morning, be our good strong continues and to very Sondra, to and everybody, a share bioprocessing XXXX as earnings applications our you, space. Thank grow Repligen expand QX the for in build year
ahead adjusting stronger-than-expected overall $X.XX delivering XX% the to quarter, Our EPS impact growth when payment a EPS $X.X and the on of for Proteins was the for reflecting top-line Navigo upfront million. our expectations performance of revenue of
again Chromatography XX% year-over-year Our Organic XX% revenues and in revenue portfolio direct-to-customer quarter for direct Filtration portfolio forecasts. growth revenue our performed second exceeded doubling Spectrum with year-over-year. well greater growth of was our the than and
increased in our XX% We also over nearly continued revenue the where Proteins first see sequential gains franchise, to quarter.
strengthen the the to continues half portfolio and load XXXX order Our we across first to of half surpass top-line of revenue. anticipate terms our in entire second still
our organic the guidance $XXX of for to We in are XX%. revenue therefore XX% the growth with to million $XXX raising million overall to year range
into to jumping partnerships I innovation, areas accomplishments want product key the Before to from strategic highlight to spectrum quarter, integration. our the few in a new
proteins Purolite on with franchise. non-Mab XX on agreements long-term to collaborations strategic a to in long-term and focused Repligen-owned Navigo, newest for monoclonal with IP Proteins, both our secures partnership the their A strategy a ligand strengthened signed of delivered characteristics ligand up we ligands the co-developed last We A platform. the Navigo with affinity our screening Sciences. those already to over stand on months. With the ligands NGL-Impac of have affinity Protein ligands agreement on market agreement that using high-throughput The has of executed and Proteins Both First, antibody partnerships. for targets. performance on that that exclusivity, come both within series Life Navigo we This June co-develop Repligen,
performance signed targets. commercial resin on AXX In quarter, the available our development and ligands Purolite's is their includes Life a NGL-Impac agarose to Jetted on now Jetted deal agreement they we commercialize Purolite speeds. new second customer royalty where milestones during product base. Navigo Proteins our A With combine the will future to achieving broader bioprocessing Sciences, addition upfront the to payments payment to contingent
So traction based customer data marketplace for on the and good in the we expect performance ligands initial feedback.
Moving now product our we column earnings new QX. last as our QX QX. discussed here launched at and to the and OPUS towards in of In orders largest the XXR additional QX, call, OPUS column expect innovation, shift we end first
systems, TFF our PH, bench systems, We adds few also This conduit, functionality platforms. a of versus to and further differentiation detection launched our providing TFF ahead competitive months a and for product module pilot-scale connectivity schedule. UV
controller second partnerships. half success strategic be our will along ATF for focus During product of with the of our our XXXX, launch the on completing driving
Spectrum on and integration into to year the and the Finally our a collective success. we're acquisition from with we're teams this effort performance, really pleased a make integration real
coming implementing global and operations the entire North completed significant team now to roll-out of sales made we on online with a the training We've QX. beginning the real progress manufacturing lean across have manufacturing at culture the the We of network. America the streamline force with in focus as products the process our
ahead are completed year. end close we million As performance revenue to our of sites of footprint. two have our strategy, we hit as for million this high the our of we the $XX filtration to poised expectations part The Spectrum smaller to believe closeout $XX business of target consolidated and of we the is the
million $X on also in achieving here synergies $X XXXX. to track are million We to of revenue
winning market in the application now filtration three strategy as franchises performance growth accelerate in areas. second franchise, quarter. our to Moving two focus continues to our main In on of the we our
seeing ATF is perhaps First, the technology we perfusion traditional second, diafiltration in and adoption in applications. market leader the increased more and processes. N-XCtraining scale-up XCell applications. ultrafiltration, fed-batch are fed-batch in in But application. the being where of is And applied & importantly perfusion technology
and strong the our In N-X vaccines that cassettes product by therapy growth from offering was we to broad Systems systems based ATF filters and pricing. fiber in lines. value-based almost in allows levels year. protein strong on the ATF number flow our gene the applications, pipes. win Demands I it success our them vaccine single-use allows to a flat hollow Asia product to main Europe year-over-year. applications. the but application to growth and therapy increased we at areas, grew performance of TFF scale. committed of next few Hollow driver customers XX% scale during sales these perspective, perfusion sheet revenue problems to membrane which similar From UF/DF gene and versus particularly the in prior fiber Our of systems growth filtration customers our a fiber line and large hollow ATF product expect years. we set flat bench continue a and single-use And observed importantly XX% solve sheet they concentration North growth not has mentioned with in This and in membranes ATF only quarter as in processes be combination will also in to for processes. the process implementing manufacturing driven of up over investing are are America to Asia, where We`re have with space and more scale, was
therapy tech our orders had the of support and goal level we a out on in applications. sales. build our the facility due cassettes had quarter flat transfer another and increased TFF some with track North Finally, cassette record gene an focus. antibody-drug service We continue to Internally, of QX to sales applications our Operationally, sheet with increased sheet completing of America bring good important our for a we with adoption sheet field teams wins flat in Marlboro conjugate are business. cassette technical to increased quarter outside to online of flat
cassettes. filtration excellence our center Our and make plan is systems to Marlboro of for
OPUS where large double-digit included franchise customer European and XX OPUS OPUS for line delivery process in the of year-on-year including PD the our Moving growth our the our XX-to chromatography had column to a to and continued for overall Highlights product columns, development. increased pharma performance demand XX-centimeter growth. quarter first
of proteins sequential performed well with the nice XX% versus business Finally, QX. growth almost
growth the the year and full-year mid-single very our expect very Overall, in in second pleased digits. good half QX. the we're with performance in We performance of
differentiated their we we very order in further expertise funnel, raise. I'll bioprocessing see are the and marketplace guidance organic half second technical customers to in it sales the are the hand With more and in we load that acceleration XXXX will strong of value Our now John confident a growth revenue and and to detail. to our bring financial over hence facilities. results products our discuss our
